A Clinical study on Thandaga vatham (Lumbar Spondylosis) with thokkanam (pidithal murai, External theraphy) Ilagu vida mutti thylam (external medicine) and pirappan kizhangu chooranam (internal medicine)

An open labelled double arm non randomized phase-II clinical trial to evaluate the therapeutic efficacy of PIRANPAN KIZHANGU CHOORNAM (INTERNAL) ILAGU VIDA MUTTI THYLAM (EXTERNAL) AND THOKKANAM (PIDITHAL MURAI EXTERNAL THERAPY) in the management of THANDAGA VATHAM (LUMBAR SPONDYLOSIS)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/12/029521

Enrollment

Registered

2020-12-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M472- Other spondylosis with radiculopathy

Interventions

Intervention1: Thokkanam(Pidithal murai) external therapy: Thokkanam(Pidithal murai) external therapy 48 days Intervention2: THOKKANAM EXTERNAL THERAPY: THOKKANAM EXTERNAL THERAPY 48 DAYS Intervention

Eligibility

Inclusion criteria

Inclusion criteria: Patients having symptoms of Pain in the lumbar region, Radiating pain to buttocks and lower limbs, stiffness present in lumbar region, Exacerbation of pain on movements, Pain increased on forward bending, Tingling sensation.(Numbness) Patients who are willing to give radiological investigation and provide blood for lab investigation. Patient willing to sign the informed consent stating that he/she will conscientiously stick to the treatment during 48 days but can option out of the trial of his/her own conscious discretion

Exclusion criteria

Exclusion criteria: Cardiac disease Auto immune diseases like Rheumatoid arthiritis, SLE, Psoriasis, Mixed connective tissue disorder. Spina bifida Osteo myelitis Renal Disease Tuberculosis in spine Patient with any other serious illness Other systemic illness Dislocation

Design outcomes

Primary

Measure	Time frame
Assessment of changes from baseline in universal pain assessment scale score at day 48 between Group I (Thokkanam External therapy) and Group II (Medicine and Thokkanam External therapy) Comparison of efficacy in patient Group I and Group IITimepoint: 48 Days	—

Secondary

Measure	Time frame
Assessment of quality of life by universal pain score scale Assessment of safety parametersTimepoint: 48 days	—

Countries

India

Contacts

Public ContactDr M Ahamed mohideen

Government siddha medical college and hospital Palayamkottai

dr.ahmed63@gmail.com9442542282

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026